Evaluation of Endothelial Dysfunction in Bipolar Affective Disorders: Serum Endocan and Urotensin-II Levels

키워드

참고문헌 (65)

1. Fagiolini A, "Prevalence, chronicity, burden and borders of bipolar disorder", J Affect Disord, 148, pp.161~169 (2013)
2. Houenou J, "Epidemiological and clinical aspects will guide the neuroimaging research in bipolar disorder", Epidemiol Psychiatr Sci, 24, pp.117~120 (2015)
3. Kulkarni J, "Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months : implications for clinical practice", BMC Psychiatry, 12, pp.228~ (2012)
4. Martino DJ, "Neurocognitive and symptomatic predictors of functional outcome in bipolar disorders : a prospective 1 year follow-up study", J Affect Disord, 116, pp.37~42 (2009)
5. Söderlund J, "Elevation of cerebrospinal fluid interleukin-1 in bipolar disorder", J Psychiatry Neurosci, 36, pp.114~118 (2011)
6. Watkins CC, "Glia and immune cell signaling in bipolar disorder : insights from neuropharmacology and molecular imaging to clinical application", Transl Psychiatry, 4, pp.e350~ (2014)
7. Stertz L, "Is bipolar disorder an inflammatory condition? The relevance of microglial activation", Curr Opin Psychiatry, 26, pp.19~26 (2013)
8. Fakhoury M, "Role of Immunity and Inflammation in the pathophysiology of neurodegenerative diseases", Neurodegener Dis, 15, pp.63~69 (2015)
9. Ather Muneer, "Bipolar Disorder: Role of Inflammation and the Development of Disease Biomarkers", PSYCHIATRY INVESTIGATION, 13(1), pp.18~33 (2016), 대한신경정신의학회[DOI]
10. Goldstein BI, "Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States", Bipolar Disord, 11, pp.657~662 (2009)
11. Dieset I, "Association between altered brain morphology and elevated peripheral endothelial markers--implications for psychotic disorders", Schizophr Res, 161, pp.222~228 (2015)
12. Goldstein BI, "Toward clinically applicable biomarkers in bipolar disorder : focus on BDNF, inflammatory markers, and endothelial function", Curr Psychiatry Rep, 15, pp.425~ (2013)
13. Kali A, "Endocan : a novel circulating proteoglycan", Indian J Pharmacol, 46, pp.579~583 (2014)
14. Canpolat U, "Role of endothelial dysfunction and endocan in atherosclerosis: point of origin or end point", Angiology (2016)[DOI]
15. Qiu CR, "Serum endothelial cell-specific molecule 1(endocan)levels in patients with acute myocardial infarction and its clinical significance", Angiology, 68, pp.354~359 (2017)
16. Kanbay A, "Endocan : a novel predictor of endothelial dysfunction in obstructive sleep apnea syndrome", Clin Respir J, 12, pp.84~90 (2018)
17. Balta S, "Endocan : a novel inflammatory indicator in cardiovascular disease", Atherosclerosis, 243, pp.339~343 (2015)
18. Westergren HU, "Insulin resistance, endothelial function, angiogenic factors and clinical outcome in non-diabetic patients with chest pain without myocardial perfusion defects", Cardiovasc Diabetol, 15, pp.36~ (2016)
19. Gungor A, "Levels of endothelial cell-specific molecule-1(ESM-1)in overt hypothyroidisim", Endocr Res, 41, pp.275~280 (2016)
20. Onan D, "Urotensin II : the old kid in town", Trends Endocrinol Metab, 15, pp.175~182 (2004)
21. Coulouarn Y, "Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors", FEBS Lett, 457, pp.28~32 (1999)
22. Ong KL, "Urotensin II : its function in health and its role in disease", Cardiovasc Drugs Ther, 19, pp.65~75 (2005)
23. Vaudry H, "International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function", Pharmacol Rev, 67, pp.214~258 (2015)
24. McDonald J, "Role of urotensin II and its receptor in health and disease", J Anesth, 21, pp.378~389 (2007)
25. Watson AM, "Urotensin II, a novel peptide in central and peripheral cardiovascular control", Peptides, 25, pp.1759~1766 (2004)
26. Maguire JJ, "Orphan-receptor ligand human urotensin II : receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1", Br J Pharmacol, 131, pp.441~446 (2000)
27. Maguire JJ, "Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues : relevance to function", Peptides, 29, pp.735~742 (2008)
28. Ono T, "Urotensin II evokes neurotransmitter release from rat cerebrocortical slices", Neurosci Lett, 440, pp.275~279 (2008)
29. Bucharles C, "Concordant localization of functional urotensin II and urotensin II-related peptide binding sites in the rat brain : Atypical occurrence close to the fourth ventricle", J Comp Neurol, 522, pp.2634~2649 (2014)
30. Dubessy C, "Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse : evidence of urotensin II at the neuromuscular junction", J Neurochem, 107, pp.361~374 (2008)
31. Bruzzone F, "Urotensin II receptor and acetylcholine release from mouse cervical spinal cord nerve terminals", Neuroscience, 170, pp.67~77 (2010)
32. Clark SD, "Urotensin II acts as a modulator of mesopontine cholinergic neurons", Brain Res, 1059, pp.139~148 (2005)
33. Hamdani N, "Immunity, inflammation, and bipolar disorder : diagnostic and therapeutic implications", Curr Psychiatry Rep, 15, pp.387~ (2013)
34. Ather Muneer, "Staging Models in Bipolar Disorder: A Systematic Review of the Literature", Clinical Psychopharmacology and Neuroscience, 14(2), pp.117~130 (2016), 대한정신약물학회
35. Bai YM, "Comparison of pro-inflammatory cytokines among patients with bipolar disorder and unipolar depression and normal controls", Bipolar Disord, 17, pp.269~277 (2015)
36. Wang TY, "Comparing clinical responses and the biomarkers of BDNF and cytokines between subthreshold bipolar disorder and bipolar II disorder", Sci Rep, 6, pp.27431~ (2016)
37. Banks WA, "Passage of cytokines across the blood-brain barrier", Neuroimmunomodulation, 2, pp.241~248 (1995)
38. Sántha P, "Restraint stress-induced morphological changes at the blood-brain barrier in adult rats", Front Mol Neurosci, 8, pp.88~ (2016)
39. Pamela Ferrari, "Depression and Mania Induce Pro-inflammatory Activation of Macrophages Following Application of Serum from Individuals with Bipolar Disorder", Clinical Psychopharmacology and Neuroscience, 16(1), pp.103~108 (2018), 대한정신약물학회[DOI]
40. Izabela G. Barbosa, "Plasma Levels of Tumor Necrosis Factor Superfamily Molecules Are Increased in Bipolar Disorder", Clinical Psychopharmacology and Neuroscience, 15(3), pp.269~275 (2017), 대한정신약물학회[DOI]
41. Taylor V, "Associations between bipolar disorder and metabolic syndrome : A review", J Clin Psychiatry, 67, pp.1034~1041 (2006)
42. Laursen TM, "Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries", PLoS One, 8, pp.e67133~ (2013)
43. Fiedorowicz JG, "Vasculopathy related to manic", hypomanic symptom burden and first-generation antipsychotics in a sub-sample from the collaborative depression study, 2012, pp.81, 235~243
44. Hope S, "Similar immune profile in bipolar disorder and schizophrenia : selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor", Bipolar Disord, 11, pp.726~734 (2009)
45. Dieset I, "Up-regulation of NOTCH4 gene expression in bipolar disorder", Am J Psychiatry, 169, pp.1292~1300 (2012)
46. Scherpereel A, "Endocan, a new endothelial marker in human sepsis", Crit Care Med, 34, pp.532~537 (2006)
47. Béchard D, "Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a", CD18(LFA-1)and blocks binding to intercellular adhesion molecule-1, 2001, pp.167, 3099~3106
48. Lassalle P, "ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines", J Biol Chem, 271, pp.20458~20464 (1996)
49. Rennel E, "Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer", Exp Cell Res, 313, pp.1285~1294 (2007)
50. Albertin G, "Urotensin-II-stimulated expression of pro-angiogenic factors in human vascular endothelial cells", Regul Pept, 172, pp.16~22 (2011)
51. Johns DG, "Urotensin-II-mediated cardiomyocyte hypertrophy : effect of receptor antagonism and role of inflammatory mediators", Naunyn Schmiedebergs Arch Pharmacol, 370, pp.238~250 (2004)
52. 박성례, "Inhibitory Effect of an Urotensin II Receptor Antagonist on Proinflammatory Activation Induced by Urotensin II in Human Vascular Endothelial Cells", Biomolecules & Therapeutics, 21(4), pp.277~283 (2013), 한국응용약물학회
53. Cadirci E, "Blocking of urotensin receptors as new target for treatment of carrageenan induced inflammation in rats", Peptides, 82, pp.35~43 (2016)
54. del Toro R, "Identification and functional analysis of endothelial tip cell-enriched genes", Blood, 116, pp.4025~4033 (2010)
55. Maurage CA, "Endocan expression and localization in human glioblastomas", J Neuropathol Exp Neurol, 68, pp.633~641 (2009)
56. Balta S, "Endocan--a novel inflammatory indicator in newly diagnosed patients with hypertension : a pilot study", Angiology, 65, pp.773~777 (2014)
57. Priya MK, "Tipping off endothelial tubes : nitric oxide drives tip cells", Angiogenesis, 18, pp.175~189 (2015)
58. You Z, "Genetic and pharmacological manipulation of urotensin II ameliorate the metabolic and atherosclerosis sequalae in mice", Arterioscler Thromb Vasc Biol, 32, pp.1809~1816 (2012)
59. Hassan GS, "Expression of urotensin-II in human coronary atherosclerosis", Peptides, 26, pp.2464~2472 (2005)
60. Jani PP, "The differential extraction and immunoluminometric assay of Urotensin II and Urotensin-related peptide in heart failure", Peptides, 40, pp.72~76 (2013)
61. Bennett RT, "Vasoconstrictive effects of endothelin-, endothelin-, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries", Thorax, 59, pp.401~407 (2004)
62. Thompson JP, "A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia : a pilot study", Anesth Analg, 97, pp.1501~1503 (2003)
63. Romanova EV, "Urotensin II in invertebrates : from structure to function in Aplysia californica", PLoS One, 7, pp.e48764~ (2012)
64. Yasuda T, "Intracerebroventricular administration of urotensin II regulates food intake and sympathetic nerve activity in brown adipose tissue", Peptides, 35, pp.131~135 (2012)
65. Yoon KH, "The relationship between serum endocan levels and depression in Alzheimer's disease", Dis Markers, 2016, pp.8254675~ (2016)

관련 논문AI추천